{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Country', 'Incidence', 'Country', 'Incidence', 'Country', 'Incidence', 'Congo', 'Djibouti', '619 (547-696)', 'Micronesia', '195 (87-347)', 'Timor-Leste', '498 (411-594)', 'Dominican', '60 (53-68)', 'Moldova', '153 (135-172)', 'Togo', '58 (47-70)', 'Republic', 'Ecuador', '54 (39-71)', 'Mongolia', '170 (149-193)', 'Turkmenistan', '64 (52-78)', 'Equatorial', '162 (142-184)', 'Morocco', '106 (97-115)', 'Tuvalu', '190 (154-228)', 'Guinea', 'Eritrea', '78 (57-103)', 'Mozambique', '551 (435-680)', 'Uganda', '161 (141-183)', 'Ethiopia', '207 (168-250)', 'Myanmar', '369 (334-406)', 'Ukraine', '94 (83-106)', 'Fiji', '67 (55-81)', 'Namibia', '561 (492-635)', 'Uzbekistan', '82 (61-107)', 'Gabon', '444 (393-497)', 'Nauru', '73 (64-83)', 'Vanuatu', '63 (52-74)', 'Gambia', '174 (145-206)', 'Nepal', '158 (139-178)', 'Vietnam', '140 (116-167)', 'Georgia', '106 (99-114)', 'Nicaragua', '58 (53-63)', 'Yemen', '48 (42-54)', 'Ghana', '165 (80-281)', 'Niger', '98 (87-110)', 'Zambia', '406 (279-557)', 'Zimbabwe', '278 (193-379)', 'Abbreviation: HIV = human immunodeficiency virus; TB = tuberculosis; WHO = World Health Organization.', 'a. Rate per 100,000 population', 'Note: ranges represent uncertainty intervals.', 'Note: The 30 WHO TB high burden countries are as follows: Angola, Bangladesh, Brazil, Cambodia, China, Congo,', 'Central African Republic, Democratic Republic of Congo, Ethiopia, India, Indonesia, Kenya, Lesotho, Liberia,', 'Mozambique, Myanmar, Namibia, Nigeria, Pakistan, Papua New Guinea, Philippines, Russian Federation, Sierra Leone,', 'South Africa, South Korea, Thailand, the United Republic of Tanzania, Viet Nam, Zambia, and Zimbabwe.', 'Source: WHO Global Tuberculosis Report 2015.', 'Amendment 2: 06 March 2019', '149', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.3 Appendix 3: Clinical Criteria for Diagnosing Anaphylaxis', 'Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:', '1. Acute onset of an illness (minutes to several hours) with involvement of the skin,', 'mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen', 'lips-tongue-uvula) AND AT LEAST 1 OF THE FOLLOWING', 'a.', 'Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced', 'PEF, hypoxemia)', 'b. Reduced BP or associated symptoms of end-organ dysfunction (e.g., hypotonia', '[collapse], syncope, incontinence)', '2. Two or more of the following that occur rapidly after exposure to a likely allergen for', 'that patient (minutes to several hours):', 'a.', 'Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen', 'lips-tongue-uvula)', 'b.', 'Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced', 'PEF, hypoxemia)', 'c.', 'Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope,', 'incontinence)', 'd.', 'Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)', '3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):', 'a.', 'Infants and children: low systolic BP (age specific) or greater than 30% decrease', 'in systolic BPa', 'b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that', \"person's baseline\", 'Abbreviations: BP = blood pressure; PEF = peak expiratory flow.', 'a. Low systolic BP for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + [2x age])', 'from 1 to 10 years, and less than 90 mm Hg from 11 to 17 years.', 'Source: Reproduced from Sampson HA, et al. J Allergy Clin Immunol. 2006. Feb;117(2):391-7.', 'Amendment 2: 06 March 2019', '150', 'Confidential']\n\n###\n\n", "completion": "END"}